Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction
27 juin 2024 08h26 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., June 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced it agreed to divest YUSIMRY (adalimumab-aqvh) to Hong Kong King-Friend...
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
09 mai 2024 16h01 HE
|
Coherus BioSciences, Inc.
– Net revenue of $77.1 million in Q1 2024 – – CRI and ENB Therapeutics development partnership for toripalimab in ovarian cancer – – New debt and royalty financing replaces $75 million...
Coherus and Superior Biologics Announce National Distribution Agreement for YUSIMRY™
13 juil. 2023 08h30 HE
|
Coherus BioSciences, Inc.
First formal distribution agreement for YUSIMRY™, a biosimilar of Humira®, at $995 per carton (two 40 mg/0.8 mL autoinjectors) representing a discount of more than 85% compared to HumiraInnovative...
Coherus Launches YUSIMRY™, a Biosimilar of Humira®, at $995 per Carton in U.S.
03 juil. 2023 08h30 HE
|
Coherus BioSciences, Inc.
–$995 per carton (two 40 mg/0.8 mL autoinjectors) represents a discount of more than 85% compared to Humira® – – YUSIMRY™ meets high unmet need by providing patients, employers, physicians and...
Mark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY™, a HUMIRA® biosimilar, available to patients
01 juin 2023 08h33 HE
|
Coherus BioSciences, Inc.
– YUSIMRY™ (adalimumab-aqvh) will be the first biologic product offered by the Mark Cuban Cost Plus Drug Company – – YUSIMRY will be available on costplusdrugs.com for $569.27 plus dispensing and...
Coherus Announces Industry-Wide Lowest List Price for Adalimumab Biosimilar YUSIMRY™ (adalimumab-aqvh) Launching in July 2023
01 juin 2023 08h30 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that the company plans to launch YUSIMRY™ (adalimumab-aqvh) in July 2023*...
Coherus Highlights Anticipated New Product Launches and Immuno-oncology Growth Strategy at Analyst Day Event
29 mars 2022 09h15 HE
|
Coherus BioSciences, Inc.
— Multiple near-term anticipated product launches and development of innovative immuno-oncology pipeline position Coherus for long-term growth – — Introducing 2026 revenue target of $1.2...
Coherus Announces U.S. FDA Approval of YUSIMRY™ (adalimumab-aqvh)
20 déc. 2021 07h59 HE
|
Coherus BioSciences, Inc.
- Approved for all eligible indications of the reference biological product, Humira® (adalimumab) - - YUSIMRY is Coherus' second FDA-approved product - REDWOOD CITY, Calif., Dec. 20, 2021 (GLOBE...